Skip to main content
S&P 5007,807.24-0.06%DOW51,850.55+0.38%NASDAQ27,245.90-0.44%BTC$81,018.00-3.35%ETH$2,413.99-5.04%GOLD$4,184.60-0.14%OIL$93.25-0.52%
Smart Investors Daily
SID Premium
MY

NASDAQ · MYGN

Myriad Genetics, Inc.

Healthcare · Medical - Diagnostics & Research

$4.20

Down-$0.11 (-2.55%)

Updated Oct 13, 2026, 3:48 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
680.86M
P/E ratio
-1.71
Dividend yield
0.00%
52-week range
$2.74 – $8.59
Volume
1.38M
Avg. volume
1.22M

Price performance · MYGN

MYGN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 12, 2026

MYGN closed at $4.20 after 21 trading sessions, up 10.82% for the selected period.

Last close
$4.20
Period change
+10.82%
Period low
$3.79
Period high
$4.58
Daily close
View OHLC price history
MYGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 12, 2026$4.30$4.32$4.19$4.201.38M
Oct 9, 2026$4.18$4.40$4.15$4.311.37M
Oct 8, 2026$4.24$4.255$4.05$4.202.26M
Oct 7, 2026$4.25$4.32$4.12$4.281.6M
Oct 6, 2026$4.62$4.826$4.22$4.281.8M
Oct 5, 2026$4.51$4.615$4.409$4.582.76M
Oct 2, 2026$4.16$4.585$4.16$4.542.28M
Oct 1, 2026$4.28$4.31$4.055$4.061.66M
Sep 30, 2026$4.28$4.385$4.22$4.311.5M
Sep 29, 2026$4.26$4.3699$4.22$4.231.6M
Sep 28, 2026$4.11$4.335$4.08$4.241.18M
Sep 25, 2026$4.16$4.25$4.065$4.171.65M
Sep 24, 2026$4.00$4.255$3.97$4.141.96M
Sep 23, 2026$4.02$4.225$3.97$4.011.66M
Sep 22, 2026$3.90$4.055$3.76$4.022.49M
Sep 21, 2026$3.93$4.035$3.87$4.011.89M
Sep 18, 2026$4.15$4.17$3.86$3.893.51M
Sep 17, 2026$3.885$4.17$3.75$4.142.83M
Sep 16, 2026$3.75$4.085$3.75$3.862.05M
Sep 15, 2026$3.795$3.98$3.695$3.884.68M
Sep 14, 2026$3.43$3.82$3.42$3.792.6M

Latest MYGN news

The latest Smart Investors Daily articles mentioning MYGN.

Stock researchCompany · Overview

MYGN research

Overview

Company profile and research snapshot.

Company profile

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.00
Implied upside
—
Analysts
—
MYGN recent ratings
DateFirmRatingTarget
Oct 2, 2026Craig-HallumBuy—
Sep 9, 2026UBSNeutral—
Sep 1, 2026Piper SandlerUnderweight—
Aug 18, 2026Stephens & Co.Equal-Weight—
Aug 3, 2026Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 4, 2026

Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets

The recent update to fair value, from US$3.37 to US$3.91 per share for Myriad Genetics, reflects a recalibration of what analysts think the stock could be worth. This shift sits alongside Street price targets that range widely from US$2 to US$8, with ratings spread from Underweight to Buy, which leaves you with a broad spectrum of risk and return views to consider. As you read on, you will see how these moving targets shape the evolving Myriad Genetics story and what to watch next. Stay...

Yahoo · Oct 3, 2026

Why Is Myriad Genetics (MYGN) Stock Soaring Today

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin raised the firm's price target on the stock to $8, StreetInsider reported.

Yahoo · Sep 24, 2026

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. This was partly due to its softer quarterly results and might have investors contemplating their next move.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By